A monthly PCSK9 shot cut LDL about 56% on top of statins

The PCSK9 pathway is one of the most productive targets in cholesterol medicine: block the PCSK9 protein and the liver clears more LDL cholesterol from the blood. Two injectable antibodies and a twice-yearly RNA drug already do this. Lerodalcibep is a newer entry — a small anti-PCSK9 binding protein, injected once a month from a small 1.2-mL dose that is stable at room temperature. LIBerate-HR, published in JAMA Cardiology, is its pivotal phase 3 efficacy and safety trial [s1].

The LDL reduction is large and the year-long safety record is clean. The missing piece is the same one that applies to a surrogate-based approval: no trial has yet shown the drug prevents the events that LDL lowering is meant to avert.

What LIBerate-HR did

LIBerate-HR was a randomised, double-blind, placebo-controlled phase 3 trial conducted at 66 clinics in 11 countries between April 23, 2021, and November 15, 2023 [s1]. It enrolled people aged 18 and older already taking maximally tolerated statin therapy who still had an LDL cholesterol of 70 mg/dL or greater with established cardiovascular disease, or 100 mg/dL or greater if at high risk of it [s1]. Participants were randomised 2:1 to monthly 1.2-mL subcutaneous lerodalcibep 300 mg or placebo for 52 weeks [s1].

Of 922 randomised participants — mean age 64.5 years (range 27-87), 414 (44.9%) female, with a mean baseline LDL cholesterol of 116.2 mg/dL (SD 43.5) — 811 (88%) completed the trial [s1]. The co-primary endpoints were the percent change in LDL cholesterol at week 52 and the mean of weeks 50 and 52 [s1]. The trial is registered as NCT04806893, with LIB Therapeutics as the sponsor [s2]; the drug received a first regulatory approval in 2026 [s3].

The numbers

By modified intention-to-treat analysis, the mean placebo-adjusted reduction in LDL cholesterol was 56.2% (SE, 2.2%) at week 52 and 62.7% (SE, 1.9%) for the mean of weeks 50 and 52 [s1]. More conservative analyses gave somewhat smaller figures — 49.7% (2.4%) and 55.3% (2.2%) by intention- to-treat using a washout-model imputation — while the per-protocol analysis gave larger ones, 60.3% (2.3%) and 65.9% (1.9%); all were significant at P < .001 [s1].

The clinical translation of that was that 555 of 615 participants (90%) taking lerodalcibep achieved both a reduction in LDL cholesterol of 50% or greater and the LDL targets recommended by guidelines during the study [s1].

Safety over the year closely matched placebo, with one expected exception. Injection-site reactions occurred in 42 of 613 participants on lerodalcibep (6.9%) versus 1 of 307 on placebo (0.3%); they were graded mild or moderate and did not lead to more treatment discontinuation, which was 26 of 613 (4.2%) on the drug and 14 of 307 (4.6%) on placebo [s1]. Sporadic anti-drug antibodies were detected in vitro but had no effect on free PCSK9 or on LDL-lowering [s1].

A big LDL drop is not the same as fewer events

LIBerate-HR delivers what a PCSK9 inhibitor is expected to: a roughly 56% placebo-adjusted fall in LDL on top of statins, letting nine in ten patients hit their targets, with a tolerability profile that looks like placebo apart from injection-site reactions [s1]. For the large group of high-risk patients who cannot get to target on statins alone, that is a meaningful addition to the toolkit, and the monthly, room-temperature format is a practical advantage over existing options.

But LDL cholesterol is a surrogate endpoint, and this trial measured only that. The case that lowering LDL this way prevents heart attacks and strokes rests on the broader, decades-deep evidence that lowering LDL reduces cardiovascular events — not on anything LIBerate-HR itself demonstrated, because it was not designed or long enough to measure outcomes [s1]. For the two older PCSK9 antibodies, dedicated outcome trials later confirmed event reduction; lerodalcibep's equivalent has not yet reported. Approval on the strength of LDL lowering [s3] is consistent with how the field regulates these drugs, but it leaves the outcome question formally open.

The funding and registration details belong in that frame too. The trial was sponsored by the company developing the drug [s2], the norm for a registration study, and the 52-week horizon is short relative to the years of treatment these patients face.

What to watch

The decisive evidence is a cardiovascular outcomes trial long and large enough to show that lerodalcibep's LDL reduction translates into fewer events, and that monthly dosing stays safe over years [s1]. Until that reports, the right reading of a 56% LDL reduction is as a strong surrogate result that earns the drug a place among LDL-lowering options — not as proof that it saves lives.

This article is informational and does not constitute medical advice.

Sources

• [s1] Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. JAMA Cardiology, 3 July 2024. https://doi.org/10.1001/jamacardio.2024.1659
• [s2] Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction. ClinicalTrials.gov identifier NCT04806893, US National Library of Medicine. https://clinicaltrials.gov/study/NCT04806893
• [s3] Lerodalcibep: First Approval. Drugs (Adis), 7 April 2026. https://doi.org/10.1007/s40265-026-02317-x